The estimated Net Worth of Scott Koenig is at least 5 百万$ dollars as of 15 February 2024. Dr Koenig owns over 42,341 units of Macrogenics Inc stock worth over 3,952,957$ and over the last 11 years he sold MGNX stock worth over 0$. In addition, he makes 1,045,415$ as CEO、 Pres & Director at Macrogenics Inc.
Dr has made over 14 trades of the Macrogenics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 42,341 units of MGNX stock worth 153,274$ on 15 February 2024.
The largest trade he's ever made was exercising 133,163 units of Macrogenics Inc stock on 11 March 2020 worth over 125,173$. On average, Dr trades about 17,287 units every 78 days since 2013. As of 15 February 2024 he still owns at least 1,091,977 units of Macrogenics Inc stock.
You can see the complete history of Dr Koenig stock trades at the bottom of the page.
Dr. Scott Koenig M.D., Ph.D. is the CEO, Pres & Director at Macrogenics Inc.
As the CEO、 Pres & Director of Macrogenics Inc, the total compensation of Dr D at Macrogenics Inc is 1,045,415$. There are no executives at Macrogenics Inc getting paid more.
Dr D is 69, he's been the CEO、 Pres & Director of Macrogenics Inc since . There are no older and 9 younger executives at Macrogenics Inc.
Scott's mailing address filed with the SEC is C/O GLYCOMIMETICS, INC., 9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Over the last 11 years, insiders at Macrogenics Inc have traded over 27,036,278$ worth of Macrogenics Inc stock and bought 4,026,274 units worth 39,875,062$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Target N Vbb Biotech Ag Bio...、Edward Hurwitz. On average, Macrogenics Inc executives and independent directors trade stock every 21 days with the average trade being worth of 132,068$. The most recent stock trade was executed by Jay Philip Siegel on 20 May 2024, trading 4,500 units of MGNX stock currently worth 16,290$.
a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!
Macrogenics Inc executives and other stock owners filed with the SEC include: